NovaBridge Biosciences disclosed that its Phase 2a study of VIS‑101, a dual VEGF‑A × ANG‑2 bispecific antibody, enrolled 38 patients in China and produced rapid, durable responses in both the 3 mg and 6 mg dose cohorts. Mean best‑corrected visual acuity improved by more than 10 Early Treatment Diabetic Retinopathy Study letters, and median central subfield thickness fell by 100–150 µm. Two‑thirds of patients remained retreatment‑free at four months and about half at six months, underscoring the drug’s potential to reduce injection frequency.
The durability profile distinguishes VIS‑101 from existing anti‑VEGF therapies that typically require monthly or bimonthly injections. By extending retreatment intervals, the candidate could address a major unmet need in wet age‑related macular degeneration, potentially positioning it as a best‑in‑class therapy and creating a competitive advantage over current market leaders such as faricimab.
Management highlighted the significance of the data, noting that “VIS‑101 produced rapid, robust and durable treatment responses, with favorable tolerability, after three loading doses. Importantly, VIS‑101 also demonstrated potential best‑in‑class durability, with nearly half of treatment‑naïve patients remaining retreatment‑free for more than six months following induction.” The company’s leadership described the results as an “important inflection point that de‑risks VIS‑101’s development and underscores the value‑creation potential of its global biotech platform.”
NovaBridge plans to launch a dose‑determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027. The company’s cash balance of $228 million is projected to fund operations through 2028, providing a solid runway for the upcoming late‑stage trials.
The announcement was well received by the market, with analysts noting the strong efficacy and durability data as key drivers of optimism. The positive Phase 2a results reinforce NovaBridge’s strategic focus on retinal vascular diseases and support confidence in the company’s pipeline and financial position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.